Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

High-Fat Diet Exacerbates Neuropathology in a Transgenic Mouse Model of Multiple System Atrophy.

Movement disorders : official journal of the Movement Disorder Society·2026
Same author

Distinct neurostructural, cognitive, and neuropsychiatric associations of plasma p-tau217, and Aβ42/40 in Parkinson's disease and aging cohorts.

Frontiers in aging neuroscience·2026
Same author

Longitudinal Decline in Electrochemical Skin Conductance Reflects Disease Progression in Multiple System Atrophy.

European journal of neurology·2026
Same author

Plasma p-tau217 Versus p-tau181 in Parkinson's Disease: Differential Associations with Alzheimer's Disease-Related Neurostructural Changes and Cognitive Function.

Movement disorders : official journal of the Movement Disorder Society·2026
Same author

Natural history and 12-month progression of multiple system atrophy in a Chinese cohort.

BMC neurology·2026
Same author

Correction: Heart rate variability provides prognostic value in multiple system atrophy.

Clinical autonomic research : official journal of the Clinical Autonomic Research Society·2026

Related Experiment Video

Updated: May 21, 2026

Focused Ultrasound Induced Blood-Brain Barrier Opening for Targeting Brain Structures and Evaluating Chemogenetic Neuromodulation
08:37

Focused Ultrasound Induced Blood-Brain Barrier Opening for Targeting Brain Structures and Evaluating Chemogenetic Neuromodulation

Published on: December 22, 2020

Methods for treating neurological conditions (WO2011159945).

Wassilios G Meissner1

  • 1Centre de référence atrophie multisystématisée, France. wassilios.meissner@chu-bordeaux.fr

Expert Opinion on Therapeutic Patents
|June 16, 2012
PubMed
Summary

This patent explores p21-activated kinase (PAK) inhibitors for neurological conditions like Huntington's disease. These compounds may reverse clinical signs by improving synaptic function, though further research is needed.

More Related Videos

A Novel Scalp Acupuncture-based Method to Target the Hand Motor Hotspot for Non-invasive Brain Stimulation
07:07

A Novel Scalp Acupuncture-based Method to Target the Hand Motor Hotspot for Non-invasive Brain Stimulation

Published on: December 19, 2025

Related Experiment Videos

Last Updated: May 21, 2026

Focused Ultrasound Induced Blood-Brain Barrier Opening for Targeting Brain Structures and Evaluating Chemogenetic Neuromodulation
08:37

Focused Ultrasound Induced Blood-Brain Barrier Opening for Targeting Brain Structures and Evaluating Chemogenetic Neuromodulation

Published on: December 22, 2020

A Novel Scalp Acupuncture-based Method to Target the Hand Motor Hotspot for Non-invasive Brain Stimulation
07:07

A Novel Scalp Acupuncture-based Method to Target the Hand Motor Hotspot for Non-invasive Brain Stimulation

Published on: December 19, 2025

Area of Science:

  • Neuroscience
  • Pharmacology
  • Biochemistry

Background:

  • Neurological disorders present significant unmet medical needs.
  • p21-activated kinases (PAK) play a role in neuronal function and morphology.
  • Dysregulation of PAK signaling is implicated in various neurological conditions.

Purpose of the Study:

  • To review a patent application concerning the use of p21-activated kinase (PAK) inhibitors for treating neurological conditions.
  • To explore the potential of novel pyrido-[2,3-d]pyrimidine-7(8H)-one compounds as PAK inhibitors.

Main Methods:

  • The patent describes compounds targeting the catalytic domain of PAK1-4.
  • Hypothesized mechanism involves modulation of dendritic spine morphology and synaptic function.
  • Preliminary preclinical data were considered.

Main Results:

  • The patent claims PAK inhibition can reverse or delay clinical signs in conditions including Huntington's disease, substance abuse, Parkinson's disease, depression, bipolar disorder, anxiety, PTSD, and neurofibromatosis.
  • Preliminary data support PAK inhibition for Huntington's disease, neurofibromatosis, and fragile X syndrome.
  • Data for other neurological conditions are currently lacking.

Conclusions:

  • PAK inhibitors represent a potential therapeutic strategy for specific neurological disorders.
  • Further comprehensive characterization of PAK's role in neurological dysfunction is required.
  • Clinical translation of these compounds will likely require many years of further development.